Patient-derived xenografts for childhood solid tumors: a valuable tool to test new drugs and personalize treatments

Clinical and Translational Oncology

Volumn 19, Issue 1, 2017, Pages 44-50

  Zarzosa, P ^a   Navarro, N ^a   Giralt, I ^a   Molist, C ^a   Almazan Moga A ^a   Vidal, I ^a   Soriano, A ^a   Segura, M F ^a   Hladun, R ^a   Villanueva, A ^b,c   Gallego, S ^a   Roma, J ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^b BELLVITGE BIOMEDICAL RESEARCH INSTITUTE IDIBELL   (Spain)

^c Bellvitge Biomedical Research Institute ^*  (Spain)

Author keywords

Animal models; PDX; Pediatric cancer; Personalized medicine; Solid tumors; Xenograft

Indexed keywords

ACUTE LYMPHOBLASTIC LEUKEMIA; CHILDHOOD CANCER; ENGRAFTMENT; GENE EXPRESSION; HUMAN; MOUSE; NONHUMAN; PERSONALIZED MEDICINE; REVIEW; SOLID TUMOR; TUMOR MICROENVIRONMENT; XENOGRAFT; ANIMAL; DRUG SCREENING; GENETICS; NEOPLASMS; PATHOLOGY; TRANSLATIONAL RESEARCH;

ANTINEOPLASTIC AGENT;

ANIMALS; ANTINEOPLASTIC AGENTS; HUMANS; MICE; NEOPLASMS; PRECISION MEDICINE; TRANSLATIONAL MEDICAL RESEARCH; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84991020846     PISSN: 1699048X     EISSN: 16993055     Source Type: Journal    
DOI: 10.1007/s12094-016-1557-2     Document Type: Review

References (46)

1. Venditti JM, Wesley RA, Plowman J. Current NCI preclinical antitumor screening in vivo: results of tumor panel screening, 1976–1982, and future directions. Adv Pharmacol Chemother. 1984;20:1–20.
2. Boyd MR. The NCI in vitro antitumor drug discovery screen: concept, implementation, and operation, 1985–1995. In: Teicher BA, editor. Anticancer drug development guide. Totowa: Humana; 1997. p. 23–42.
3. Daniel VC, Marchionni L, Hierman JS, Rhodes JT, Devereux WL, Rudin CM, et al. A primary xenograft model of small-cell lung cancer reveals irreversible changes in gene expression imposed by culture in vitro. Cancer Res. 2009;69:3364–73.
4. Tentler JJ, Tan AC, Weekes CD, Jimeno A, Leong S, Pitts TM, et al. Patient-derived tumor xenografts as models for oncology drug development. Nat Rev Clin Oncol. 2012;9:338–50.
5. Kim MP, Evans DB, Wang H, Abbruzzese JL, Fleming JB, Gallick GE. Generation of orthotopic and heterotopic human pancreatic cancer xenografts in immunodeficient mice. Nat Protoc. 2009;4(11):1670–80.
6. Hidalgo M, Bruckheimer E, Rajeshkumar NV, Garrido-Laguna I, De Oliveira E, Rubio-Viqueira B, et al. A pilot clinical study of treatment guided by personalized tumorgrafts in patients with advanced cancer. Mol Cancer Ther. 2011;10(8):1311–6.
7. Blattmann C, Thiemann M, Stenzinger A, Roth EK, Dittmar A, Witt H, et al. Establishment of a patient-derived orthotopic osteosarcoma mouse model. J Transl Med. 2015;13:136.
8. Monsma DJ, Monks NR, Cherba DM, Dylewski D, Eugster E, Jahn H, et al. Genomic characterization of explant tumorgraft models derived from fresh patient tumor tissue. J Transl Med. 2012;10:125.
9. Shorthouse AJ, Peckham MJ, Smyth JF, Steel GG. The therapeutic response of bronchial carcinoma xenografts: a direct patient-xenograft comparison. Br J Cancer Suppl. 1980;4:142–5.
10. Fujita M, Hayata S, Taguchi T. Relationship of chemotherapy on human cancer xenografts in nude mice to clinical response in donor patient. J Surg Oncol. 1980;15(3):211–9.
11. Houghton JA, Houghton PJ, Green AA. Chemotherapy of childhood rhabdomyosarcomas growing as xenografts in immune-deprived mice. Cancer Res. 1982;42:535–9.
12. Fiebig HH, Neumann HA, Henss H, Koch H, Kaiser D, Arnold H. Development of three human small cell lung cancer models in nude mice. Recent Results Cancer Res. 1985;97:77–86.
13. Vidal A, Muñoz C, Guillén MJ, Moretó J, Puertas S, Martínez-Iniesta M, et al. Lurbinectedin (PM01183), a new DNA minor groove binder, inhibits growth of orthotopic primary graft of cisplatin-resistant epithelial ovarian cancer. Clin Cancer Res. 2012;18(19):5399–411.
14. Hidalgo M, Amant F, Biankin AV, Budinská E, Byrne AT, Caldas C, et al. Patient-derived xenograft models: an emerging platform for translational cancer research. Cancer Discov. 2014;4(9):998–1013.
15. Johnson JI, Decker S, Zaharevitz D, Rubinstein LV, Venditti JM, Schepartz S, et al. Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials. Br J Cancer. 2001;84:1424–31.
16. Zayed AA, Mandrekar SJ, Haluska P. Molecular and clinical implementations of ovarian cancer mouse avatar models. Chin Clin Oncol. 2015;4(3):30.
17. Juliachs M, Muñoz C, Moutinho CA, Vidal A, Condom E, Esteller M, et al. The PDGFRβ-AKT pathway contributes to CDDP-acquired resistance in testicular germ cell tumors. Clin Cancer Res. 2014;20(3):658–67.
18. Ambrogio C, Gómez-López G, Falcone M, Vidal A, Nadal E, Crosetto N, et al. Combined inhibition of Ddr1 and notch signaling is a therapeutic strategy for KRAS-driven lung adenocarcinoma. Nat Med. 2016;22(3):270–7.
19. Talmadge JE, Singh RK, Fidler IJ, Raz A. Murine models to evaluate novel and conventional therapeutic strategies for cancer. Am J Pathol. 2007;170:793–804.
20. Rubio-Viqueira B, Hidalgo M. Direct in vivo xenograft tumor model for predicting chemotherapeutic drug response in cancer patients. Clin Pharmacol Ther. 2009;85:217–21.
21. Bergamaschi A, Hjortland GO, Triulzi T, Sørlie T, Johnsen H, Ree AH, et al. Molecular profiling and characterization of luminal-like and basal-like in vivo breast cancer xenograft models. Mol Oncol. 2009;3(5–6):469–82.
22. Braekeveldt N, Wigerup C, Gisselsson D, Mohlin S, Merselius M, Beckman S, et al. Neuroblastoma patient-derived orthotopic xenografts retain metastatic patterns and geno- and phenotypes of patient tumours. Int J Cancer. 2015;136(5):E252–61.
23. Grovas A, Fremgen A, Rauck A, Ruymann FB, Hutchinson CL, Winchester DP, et al. The national cancer data base report on patterns of childhood cancers in the United States. Cancer. 1997;80(12):2321–32.
24. Houghton PJ, Adamson PC, Blaney S, Fine HA, Gorlick R, Haber M, et al. Testing of new agents in childhood cancer preclinical models: meeting summary. Clin Cancer Res. 2002;8(12):3646–57.
25. Houghton PJ, Morton CL, Tucker C, Payne D, Favours E, Cole C, et al. The pediatric preclinical testing program: description of models and early testing results. Pediatr Blood Cancer. 2007;49:928–40.
26. Carol H, Houghton PJ, Morton CL, Kolb EA, Gorlick R, Reynolds P, et al. Initial testing of topotecan by the pediatric preclinical testing program. Pediatr Blood Cancer. 2010;54(5):707–15.
27. Stewart E, Federico S, Karlstrom A, Shelat A, Sablauer A, Pappo A, et al. The childhood solid tumor network: a new resource for the developmental biology and oncology research communities. Dev Biol. 2016;411:287–93.
28. The EurOPDX consortium. 2016. http://europdx.eu/. Accessed 29 July 2016.
29. Nicolle D, Fabre M, Simon-Coma M, Gorse A, Kappler R, Nonell L, et al. Patient-derived xenografts from pediatric liver cancer predict tumor recurrence and advise clinical management. Hepatology. 2016;64(4):1121–35.
30. Bissig-Choisat B, Kettlun-Leyton C, Legras XD, Zorman B, Barzi M, Chen LL, et al. Novel patient-derived xenograft and cell line models for therapeutic testing of pediatric liver cancer. J Hepatol. 2016;65(2):325–33.
31. Braekeveldt N, Wigerup C, Tadeo I, Beckman S, Sandén C, Jönsson J, et al. Neuroblastoma patient-derived orthotopic xenografts reflect the microenvironmental hallmarks of aggressive patient tumours. Cancer Lett. 2016;375(2):384–9.
32. Rodríguez-Hernández CJ, Mateo-Lozano S, García M, Casalà C, Briansó F, Castrejón N, et al. Cinacalcet inhibits neuroblastoma tumor growth and upregulates cancer-testis antigens. Oncotarget. 2016;7(13):16112–29.
33. Krytska K, Ryles HT, Sano R, Raman P, Infarinato NR, Hansel TD, et al. Crizotinib synergizes with chemotherapy in preclinical models of neuroblastoma. Clin Cancer Res. 2016;22(4):948–60.
34. Geier B, Kurmashev D, Kurmasheva RT, Houghton PJ. Preclinical childhood sarcoma models: drug efficacy biomarker identification and validation. Front Oncol. 2015;5:193.
35. Monsma DJ, Cherba DM, Richardson PJ, Vance S, Rangarajan S, Dylewski D, et al. Using a rhabdomyosarcoma patient-derived xenograft to examine precision medicine approaches and model acquired resistance. Pediatr Blood Cancer. 2014;61:1570–7.
36. Saulnier Sholler GL, Bond JP, Bergendahl G, Dutta A, Dragon J, Neville K, et al. Feasibility of implementing molecular-guided therapy for the treatment of patients with relapsed or refractory neuroblastoma. Cancer Med. 2015;4(6):871–86.
37. Bult CJ, Krupke DM, Begley DA, Richardson JE, Neuhauser SB, Sundberg JP, et al. Mouse Tumor Biology (MTB): a database of mouse models for human cancer. Nucleic Acids Res. 2015;43(Database issue): D818–D824.
38. Siolas D, Hannon GJ. Patient-derived tumor xenografts: transforming clinical samples into mouse models. Cancer Res. 2013;73(17):5315–9.
39. Cassidy JW, Caldas C, Bruna A. Maintaining tumour heterogeneity in patient-derived tumour xenografts. Cancer Res. 2015;75(15):2963–8.
40. Shultz LD, Brehm MA, Garcia-Martinez JV, Greiner D. Humanized mice for immune system investigation: progress, promise and challenges. Nature Rev Immunol. 2012;12(11):786–98.
41. Singh Z. Applications and toxicity of graphene family nanomaterials and their composites. Nanotechnol Sci Appl. 2016;9:15–28.
42. De la Fuente A, Alonso-Alconada L, Costa C, Cueva J, Garcia-Caballero T, Lopez-Lopez R, et al. M-trap: exosome-based capture of tumor cells as a new technology in peritoneal metastasis. J Natl Cancer Inst. 2015;107:1–10.
43. Dong Z, Imai A, Krishnamurthy S, Zhang Z, Zeitlin BD, Nör JE. Xenograft tumors vascularized with murine blood vessels may overestimate the effect of anti-tumor drugs: a pilot study. PLoS One. 2013;8(12):e84236.
44. Straussman R, Morikawa T, Shee K, Barzily-Rokni M, Qian ZR, Du J, et al. Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature. 2012;487(7408):500–4.
45. Green JL, La J, Yum KW, Desai P, Rodewald LW, Zhang X, et al. Paracrine Wnt signaling both promotes and inhibits human breast tumor growth. Proc Natl Acad Sci USA. 2013;110(17):6991–6.
46. DeRose YS, Wang G, Lin YC, Bernard PS, Buys SS, Ebbert MT, et al. Tumor grafts derived from women with breast cancer authentically reflect tumor pathology, growth, metastasis and disease outcomes. Nat Med. 2011;17(11):1514–20.